Drug Profile
Research programme: selective estrogen receptor modulators - Karo Bio/Merck & Co
Alternative Names: ER programme; Estrogen receptor modulators programme; SERM programmeLatest Information Update: 31 Jul 2013
Price :
$50
*
At a glance
- Originator Karo Bio
- Developer Merck & Co
- Class
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Female genital diseases; Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 30 Sep 2012 Discontinued - Preclinical for Gynaecological disorders in Sweden (unspecified route)
- 30 Sep 2012 Discontinued - Preclinical for Menopausal syndrome in Sweden (unspecified route)
- 30 Sep 2012 Discontinued - Preclinical for Postmenopausal osteoporosis in Sweden (unspecified route)